ERBB2 and neoplasm: By implementing both retargeting and shielding strategies, we achieved viral gene delivery to two different tumor models overexpressing HER2 or EGFR in vivo, reduced the off-targeting to the liver and increased the tumor-to-liver-ratio of the expressed transgene by a factor of about 2500 compared to naive HAdV5 vectors.